

# Lorenzo Calvetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9603691/publications.pdf>

Version: 2024-02-01

30  
papers

875  
citations

759233

12  
h-index

526287

27  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1824  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 865-874.	4.2	11
2	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	3
3	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , 2022, 127, 383-393.	6.4	36
4	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , 2021, 10, 202-220.	2.8	29
5	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
6	A nurse-led telephone triage for the prevention and control of COVID-19 spread in an oncology department.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13617-e13617.	1.6	0
7	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1221-1232.	3.1	2
8	Home-Based Management of Patients With Cancer Experiencing Treatment-Induced Toxicities With a Nurse-Led Telephone Triage (the NTT Study). <i>JCO Oncology Practice</i> , 2021, , OP.21.00192.	2.9	1
9	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096846.	3.2	14
10	<p>Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harboring <em>EGFR</em> G719A/V769M Complex Mutation</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12027-12031.	2.0	0
11	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , 2020, 25, e1996-e2005.	3.7	21
12	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 319-326.	3.1	12
13	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020, 37, 1145-1155.	2.9	102
14	Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3046-3046.	1.6	1
15	Home-based management of cancer patients (CPs) experiencing toxicities while on anticancer treatment: The impact of a nurse-led telephone triage (NTT).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2002-2002.	1.6	0
16	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
17	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	6.4	24
18	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. <i>British Journal of Cancer</i> , 2019, 120, 522-526.	6.4	11

#	ARTICLE	IF	CITATIONS
19	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 1128-1136.	3.7	156
20	Influence and mechanism of lung cavitation development on antiangiogenic therapy: is cavitation the new caveat?. <i>Translational Lung Cancer Research</i> , 2019, 8, 319-322.	2.8	6
21	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , 2019, 24, e318-e326.	3.7	5
22	FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 5694-5700.	1.4	1
23	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
24	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the "BRAF, BeCool" platform.. <i>Journal of Clinical Oncology</i> , 2018, 36, 639-639.	1.6	2
25	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
26	New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. <i>Frontiers in Pharmacology</i> , 2017, 8, 354.	3.5	165
27	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. <i>Frontiers in Pharmacology</i> , 2016, 7, 331.	3.5	13
28	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	6.4	56
29	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1359-1370.	3.1	13
30	Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 6660-6669.	1.9	33